Form 4: Vistagen Director Granted Stock Options Under 10b5-1 Plan

Vistagen Therapeutics Director Joanne Curley was granted 17,600 non-qualified stock options with an exercise price of $3.61, vesting monthly over one year.

Summary

• Joanne Curley, a Director of Vistagen Therapeutics, Inc., was granted 17,600 non-qualified stock options.
• The options have an exercise price of $3.61 per share.
• The grant date for these options is September 9, 2025.
• The options will vest in twelve equal monthly installments, commencing from the grant date.
• The expiration date for these options is September 9, 2035.
• This transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged purchase or sale plan.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard compensation practice designed to align interests with shareholders. It's a routine event, not indicative of significant positive or negative operational news, but generally viewed as a positive for governance and incentive alignment.

Positives

• The grant of stock options aligns the interests of Director Joanne Curley with those of shareholders, incentivizing long-term company performance.
• The transaction is part of a pre-arranged Rule 10b5-1 plan, indicating a structured and transparent approach to insider compensation.

Negatives

• No direct negatives are apparent from this routine insider compensation filing.

Risks

• The value of the stock options is subject to the future market price of Vistagen Therapeutics, Inc. common stock, which may decline below the exercise price.
• Future stock price volatility could impact the ultimate realized value of these options.

Future Outlook

The options are scheduled to vest in twelve equal monthly installments starting September 9, 2025, indicating a future increase in the director's beneficial ownership of exercisable options over the next year.

Industry Context

The grant of stock options is a common form of executive and director compensation in the biotechnology and pharmaceutical industry, aiming to incentivize long-term performance and align management interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• While the specific number of options and exercise price are company-specific, the mechanism is consistent with industry practices for attracting and retaining qualified board members.
• Without specific peer company compensation data, a direct quantitative comparison is not feasible from this filing alone.

Corporate Governance

Stakeholder Impact

• Shareholders: Interests are further aligned with the director through equity incentives, potentially fostering long-term value creation.

Next Steps

• Monthly vesting of 17,600 stock options over the next twelve months, commencing September 9, 2025.
• Potential exercise of vested options by Director Curley in the future.

Key Dates

Keywords

Vistagen Therapeutics, VTGN, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Incentive Plan, 10b5-1 Plan